Angiotensin AT4 receptor ligand interaction with cystinyl aminopeptidase and aminopeptidase N: [125I]Angiotensin IV only binds to the cystinyl aminopeptidase apo-enzyme.

Due to its high affinity for [(125)I]Angiotensin IV, cystinyl aminopeptidase (CAP) has recently been assigned as the 'angiotensin AT(4) receptor'. Since the aminopeptidase N (AP-N) activity is also susceptible to inhibition by Angiotensin IV, it might represent an additional target for this peptide. Based on [(125)I]Angiotensin IV binding and catalytic activity measurements, we compared the ligand interaction properties of recombinant human CAP and human AP-N. Both enzymes displayed distinct pharmacological profiles. Although their activity is inhibited by Angiotensin IV and LVV-hemorphin 7, both peptides are more potent CAP-inhibitors. On the other hand, substance P and l-methionine have a higher potency for AP-N. High affinity binding of [(125)I]Angiotensin IV to CAP occurs in the presence of chelators but not to AP-N in either the absence or presence of chelators. These differences were exploited to determine whether CAP and/or AP-N are present in different cell lines (CHO-K1, COS-7, HEK293, SK-N-MC and MDBK). We provide evidence that CAP predominates in these cell lines and that, comparatively, CHO-K1 cells display the highest level of this enzyme.

[1]  Y. Michotte,et al.  Synergistic modulation of cystinyl aminopeptidase by divalent cation chelators. , 2004, Biochemical pharmacology.

[2]  J. Wright,et al.  Autoradiographic Identification of Kidney Angiotensin IV Binding Sites and Angiotensin IV-Induced Renal Cortical Blood Flow Changes in Rats , 1998, Peptides.

[3]  N. Matsuoka,et al.  Changes in brain somatostatin in memory-deficient rats: comparison with cholinergic markers , 1995, Neuroscience.

[4]  J. Braszko,et al.  Angiotensin ii-(3–8)-hexapeptide affects motor activity, performance of passive avoidance and a conditioned avoidance response in rats , 1988, Neuroscience.

[5]  E. Block,et al.  Angiotensin IV receptor-mediated activation of lung endothelial NOS is associated with vasorelaxation. , 1998, American journal of physiology. Lung cellular and molecular physiology.

[6]  Veerle Kersemans,et al.  Endogenous cystinyl aminopeptidase in Chinese hamster ovary cells: characterization by [125I]Ang IV binding and catalytic activity. , 2004, Biochemical pharmacology.

[7]  L. Stubley,et al.  Contributions of the Brain Angiotensin IV–AT4 Receptor Subtype System to Spatial Learning , 1999, The Journal of Neuroscience.

[8]  Y. Michotte,et al.  Cellular targets for angiotensin II fragments: pharmacological and molecular evidence , 2002, Journal of the renin-angiotensin-aldosterone system : JRAAS.

[9]  T. Tetaz,et al.  The Globin Fragment LVV‐Hemorphin‐7 Is an Endogenous Ligand for the AT4 Receptor in the Brain , 1997, Journal of neurochemistry.

[10]  M. Herrmann,et al.  Aminopeptidase N/CD13 is directly linked to signal transduction pathways in monocytes. , 2000, Cellular immunology.

[11]  R. Aebersold,et al.  Cloning and Characterization of a Novel Insulin-regulated Membrane Aminopeptidase from Glut4 Vesicles (*) , 1995, The Journal of Biological Chemistry.

[12]  R. Handa,et al.  Characterization and function of the bovine kidney epithelial angiotensin receptor subtype 4 using angiotensin IV and divalinal angiotensin IV as receptor ligands. , 1999, The Journal of pharmacology and experimental therapeutics.

[13]  S. Mizutani,et al.  Involvement of the V2 receptor in vasopressin-stimulated translocation of placental leucine aminopeptidase/oxytocinase in renal cells. , 2003, European journal of biochemistry.

[14]  A. Kehlen,et al.  CD13—not just a marker in leukemia typing , 1999, Immunology Today.

[15]  E. Kramár,et al.  Angiotensin II- and IV-induced changes in cerebral blood flow Roles of AT1 AT2, and AT4 receptor subtypes , 1997, Regulatory Peptides.

[16]  P. Erne,et al.  Stimulation of DNA and RNA synthesis in cultured rabbit cardiac fibroblasts by angiotensin IV. , 1995, Clinical science.

[17]  E. Kramár,et al.  Characterization of the binding properties and physiological action of divalinal-angiotensin IV, a putative AT4 receptor antagonist , 1996, Regulatory Peptides.

[18]  R. Ardaillou,et al.  Hemorphins inhibit angiotensin IV binding and interact with aminopeptidase N , 1998, Peptides.

[19]  S. Ye,et al.  Angiotensin AT4 ligands are potent, competitive inhibitors of insulin regulated aminopeptidase (IRAP) , 2003, Journal of neurochemistry.

[20]  G. Paxinos,et al.  Distribution of angiotensin IV binding sites (AT4 receptor) in the human forebrain, midbrain and pons as visualised by in vitro receptor autoradiography , 2000, Journal of Chemical Neuroanatomy.

[21]  J. Engberg,et al.  Complete amino acid sequence of human intestinal aminopeptidase N as deduced from cloned cDNA , 1988, FEBS letters.

[22]  J. Harding,et al.  Attenuation of scopolamine-induced spatial learning impairments by an angiotensin IV analog , 1998, Regulatory Peptides.

[23]  S. Mizutani Physiological roles of placental proteases in feto-placental homeostasis. , 1998, Nagoya journal of medical science.

[24]  J. Harding,et al.  Elucidation of a specific binding site for angiotensin II(3-8), angiotensin IV, in mammalian heart membranes. , 1993, The Journal of pharmacology and experimental therapeutics.

[25]  R. Simpson,et al.  Evidence That the Angiotensin IV (AT4) Receptor Is the Enzyme Insulin-regulated Aminopeptidase* , 2001, The Journal of Biological Chemistry.

[26]  John W. Wright,et al.  The brain angiotensin system and extracellular matrix molecules in neural plasticity, learning, and memory , 2004, Progress in Neurobiology.

[27]  G. Kovacs,et al.  Peptidergic modulation of learning and memory processes. , 1994, Pharmacological reviews.

[28]  A. Baron,et al.  Evidence for defects in the trafficking and translocation of GLUT4 glucose transporters in skeletal muscle as a cause of human insulin resistance. , 1998, The Journal of clinical investigation.

[29]  J. Wright,et al.  Structural analysis of angiotensin IV receptor (AT4) from selected bovine tissues. , 1999, The Journal of pharmacology and experimental therapeutics.

[30]  Y. Michotte,et al.  Metal ion modulation of cystinyl aminopeptidase. , 2005, The Biochemical journal.

[31]  G. Lienhard,et al.  Trafficking kinetics of the insulin-regulated membrane aminopeptidase in 3T3-L1 adipocytes. , 1997, Biochemical and biophysical research communications.

[32]  L. Hunyady,et al.  Ligand binding and functional properties of human angiotensin AT1 receptors in transiently and stably expressed CHO-K1 cells. , 2005, European journal of pharmacology.

[33]  B. Alescio-Lautier,et al.  Neuromodulation of memory in the hippocampus by vasopressin. , 2000, European journal of pharmacology.

[34]  Axel Bossuyt,et al.  Comparative biodistribution of iodinated amino acids in rats: selection of the optimal analog for oncologic imaging outside the brain. , 2003, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[35]  K. Grove,et al.  Central angiotensin IV binding sites: distribution and specificity in guinea pig brain. , 1993, The Journal of pharmacology and experimental therapeutics.

[36]  J. Lee,et al.  Effect of I.C.V. injection of AT4 receptor ligands, NLE1-angiotensin IV and LVV-hemorphin 7, on spatial learning in rats , 2004, Neuroscience.

[37]  T. Schwartz,et al.  Biosynthesis of peptide precursors and protease inhibitors using new constitutive and inducible eukaryotic expression vectors , 1990, FEBS letters.

[38]  Y. Cheng,et al.  Relationship between the inhibition constant (K1) and the concentration of inhibitor which causes 50 per cent inhibition (I50) of an enzymatic reaction. , 1973, Biochemical pharmacology.

[39]  S. Mizutani,et al.  Human Placental Leucine Aminopeptidase/Oxytocinase , 1996, The Journal of Biological Chemistry.

[40]  J. Egido,et al.  Angiotensin IV Activates the Nuclear Transcription Factor-&kgr;B and Related Proinflammatory Genes in Vascular Smooth Muscle Cells , 2005, Circulation research.

[41]  T. Kristensen,et al.  Mutational analysis of the active site of human insulin-regulated aminopeptidase. , 2001, European journal of biochemistry.

[42]  D. Scheinberg,et al.  Substance P and bradykinin are natural inhibitors of CD13/aminopeptidase N. , 1995, Biochemical and biophysical research communications.

[43]  T. Mustafa,et al.  Characterization of the AT4 receptor in a human neuroblastoma cell line (SK‐N‐MC) , 2001, Journal of neurochemistry.

[44]  Joohyung Lee,et al.  AT4 receptor is insulin-regulated membrane aminopeptidase: potential mechanisms of memory enhancement , 2003, Trends in Endocrinology & Metabolism.